Regulation of prostaglandin transporters in colorectal neoplasia

Cancer Prevention Research

Volumn 1, Issue 2, 2008, Pages 93-99

  Holla, Vijaykumar R ^a   Backlund, Michael G ^b   Yang, Peying ^a   Newman, Robert A ^a   DuBois, Raymond N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCC4 PROTEIN, HUMAN; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; PROSTAGLANDIN E2; SLCO2A1 PROTEIN, HUMAN;

ADENOMA; ANIMAL; ARTICLE; BIOLOGICAL MODEL; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; INTESTINE POLYP; METABOLISM; MOUSE; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; CARRIER PROTEINS; COLORECTAL NEOPLASMS; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, APC; HUMANS; INTESTINAL POLYPS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 57249086646     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-07-0009     Document Type: Article

References (29)

1. Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004;70:101-13.
2. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
3. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13:1205-11.
4. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
5. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
6. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994;35:675-8.
7. Mauritz I, Westermayer S, Marian B, Erlach N, Grusch M, Holzmann K. Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells. Br J Cancer 2006;94: 1718-25.
8. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276: 18075-81.
9. Balch CM, Dougherty PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984;95: 71-7.
10. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
11. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
12. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 2004;6:285-95.
13. Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004;65:973-8.
14. Schuster VL. Prostaglandin transport. Prostaglandins Other Lipid Mediat 2002;68-9:633-47.
15. Bao Y, Pucci ML, Chan BS, Lu R, Ito S, Schuster VL. Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 2002;282:F1103-10.
16. Lu R, Schuster VL. Molecular cloning of the gene for the human prostaglandin transporter hPGT: gene organization, promoter activity, and chromosomal localization. Biochem Biophys Res Commun 1998;246:805-12.
17. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005; 280:3217-23.
18. Mann JR, Backlund MG, Buchanan FG, et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006;66:6649-56.
19. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD +linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72.
20. Wolf I, O'Kelly J, Rubinek T, et al. 15-hydroxy-prostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66: 7818-23.
21. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxy-prostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A2004;101:17468-73.
22. Kempen EC, Yang P, Felix E, Madden T, Newman RA. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 2001;297:183-90.
23. Yang P, Felix E, Madden T, Fischer SM, Newman RA. Quantitative high performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem 2002;308: 168-77.
24. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99: 2254-9.
25. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2003;100:9244-9.
26. Zhu T, Gobeil F, Vazquez-Tello A, et al. Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can J Physiol Pharmacol 2006;84:377-91.
27. Boultwood J, Wainscoat JS. Gene silencing by DNAme thylation in haematological malignancies. Br J Haematol 2007;138:3-11.
28. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev 2007;8:286-98.
29. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.